Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$17 Mln
Revenue (TTM)
$48 Mln
Net Profit (TTM)
$-22 Mln
ROE
-0.9 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.7
Industry P/E
--
EV/EBITDA
-0.5
Div. Yield
0 %
Debt to Equity
1.4
Book Value
$0.6
EPS
$-0.7
Face value
--
Shares outstanding
36,725,900
CFO
$-94.79 Mln
EBITDA
$-86.19 Mln
Net Profit
$-126.98 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Chembio Diagnostics (CEMI)
| 106.8 | 16.7 | 30.0 | -27.8 | -69.2 | -43.6 | -20.6 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Chembio Diagnostics (CEMI)
| -80.7 | -76.0 | 4.2 | -19.4 | -30.8 | 20.6 | 27.6 |
|
S&P Small-Cap 600
| -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Chembio Diagnostics (CEMI)
|
0.5 | 16.7 | 48.3 | -23.3 | -42.2 | -89.5 | -- | 0.7 |
| 25.0 | 2,375.4 | 12.9 | -113.6 | -993.9 | 133.4 | -- | 5.3 |
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID 19, HIV and Syphilis, and Zika... virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, NEXT GENERATION DPP, and DPP trademarks, as well as sells its products directly through distributors to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.S. government agencies, such as Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Medford, New York. As of April 27, 2023, Chembio Diagnostics, Inc. operates as a subsidiary of Biosynex SA. Read more
Pres, CEO & Director
Mr. Richard L. Eberly
Pres, CEO & Director
Mr. Richard L. Eberly
Headquarters
Hauppauge, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Chembio Diagnostics Inc (CEMI) is $0.46 (NASDAQ) as of 27-Apr-2023 16:00 EDT. Chembio Diagnostics Inc (CEMI) has given a return of -69.18% in the last 3 years.
Since, TTM earnings of Chembio Diagnostics Inc (CEMI) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.30
|
0.40
|
|
2021
|
-0.81
|
0.80
|
|
2020
|
-3.54
|
3.25
|
|
2019
|
-5.67
|
3.23
|
|
2018
|
-10.07
|
2.38
|
The 52-week high and low of Chembio Diagnostics Inc (CEMI) are Rs -- and Rs -- as of 04-Apr-2026.
Chembio Diagnostics Inc (CEMI) has a market capitalisation of $ 17 Mln as on 27-Apr-2023. As per SEBI classification, it is a Small Cap company.
Before investing in Chembio Diagnostics Inc (CEMI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.00
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.